Hypoxia and hypoxia inducible factors: Diverse roles in liver diseases

Hypoxia has been shown to have a role in the pathogenesis of several forms of liver disease. The hypoxia inducible factors (HIFs) are a family of evolutionarily conserved transcriptional regulators that affect a homeostatic response to low oxygen tension and have been identified as key mediators of...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology (Baltimore, Md.) Vol. 55; no. 2; pp. 622 - 633
Main Authors: Nath, Bharath, Szabo, Gyongyi
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-02-2012
Wiley
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypoxia has been shown to have a role in the pathogenesis of several forms of liver disease. The hypoxia inducible factors (HIFs) are a family of evolutionarily conserved transcriptional regulators that affect a homeostatic response to low oxygen tension and have been identified as key mediators of angiogenesis, inflammation, and metabolism. In this review we summarize the evidence for a role of HIFs across a range of hepatic pathophysiology. We describe regulation of the HIFs and review investigations that demonstrate a role for HIFs in the development of liver fibrosis, activation of innate immune pathways, hepatocellular carcinoma, as well as other liver diseases in both human disease as well as murine models. (HEPATOLOGY 2012;)
Bibliography:ark:/67375/WNG-W4JNLK2J-3
istex:D55F4F078BEF3300EE2C75817EC9AE3AFE335D8C
Potential conflict of interest: Dr. Szabo is a consultant for, advises, and is on the speakers' bureau of Vertex, Conatus, GlaxoSmithKline, Bristol-Myers Squibb, Idenix, Idera, Integrated Therapeutics, Johnson & Johnson, Novartis, Novelos, Ocera, Roche, Schering-Plough, Wyeth, SmithKline Beechman, Ikaria, and FALK.
ArticleID:HEP25497
Potential conflict of interest: Dr. Szabo is a consultant for, advises, and is on the speakers' bureau of Vertex, Conatus, GlaxoSmithKline, Bristol‐Myers Squibb, Idenix, Idera, Integrated Therapeutics, Johnson & Johnson, Novartis, Novelos, Ocera, Roche, Schering‐Plough, Wyeth, SmithKline Beechman, Ikaria, and FALK.
fax: 508‐856‐4770
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0270-9139
1527-3350
DOI:10.1002/hep.25497